Evotec has been granted a patent for an LpxC inhibitor compound, which can be used in the treatment of gram-negative bacterial infections like urinary tract infections. The patent also covers methods of making the compound and pharmaceutical compositions containing it. A specific process for the preparation of Formula 15 is claimed. GlobalData’s report on Evotec gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Evotec, NSAID cancer drugs was a key innovation area identified from patents. Evotec's grant share as of September 2023 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11731962B2) discloses a process for the preparation of a compound referred to as Formula 15. The process involves several steps and conditions. In one embodiment, the oxidation reagent system used is a TEMPO/bleach system, and the suitable solvent is chosen from options such as acetonitrile, dichloromethane, chloroform, dichloroethane, hexanes, water, or a combination thereof. The temperature for this step ranges from about 0°C to about 5°C. The compound of Formula 14, a precursor to Formula 15, is prepared by contacting a compound of Formula 13. This step involves the use of a suitable borohydride reagent, such as lithium borohydride, and a solvent mixture of tetrahydrofuran and ethanol. The temperature for this step ranges from about 0°C to about 25°C.
After the preparation of Formula 14, it can be crystallized from various solvents including acetonitrile, methanol, ethanol, isopropyl alcohol, acetone, methyl acetate, ethyl acetate, dichloromethane, chloroform, diethyl ether, diisopropyl ether, tert-butyl methyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, benzene, toluene, petroleum ether, pentane, hexane, heptane, cyclohexane, acetic acid, water, or a mixture thereof.
The compound of Formula 13 is prepared by contacting a compound of Formula 12. This step involves the use of a suitable base, LiHDMS, and a solvent, tetrahydrofuran. The reaction is performed at a temperature of about -25°C to about -15°C, and the compound of Formula 12 is reacted with the base for a specific duration before the addition of the compound of Formula 9.
The process also includes additional steps involving the reaction of Formula 15 with other compounds, such as Formula 16 and Formula 20, to produce desired products. These steps involve the use of specific reducing agents, solvents, and reaction conditions.
The patent also mentions the crystallization of one of the final products, referred to as Compound A, from various solvents similar to the ones mentioned earlier.
Overall, the granted patent provides a detailed process for the preparation of Formula 15 and its subsequent reactions with other compounds to produce desired products. The patent covers specific reagents, solvents, and reaction conditions used in each step of the process.
To know more about GlobalData’s detailed insights on Evotec, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
